What Is Junctional Tachycardia: Symptoms and Treatment

Junctional tachycardia is an abnormally fast heart rhythm that originates in or near the atrioventricular (AV) node, the small cluster of cells between the heart’s upper and lower chambers that normally acts as an electrical relay station. Heart rates during episodes typically range from about 120 to 250 beats per minute, and the rhythm is often irregular with a characteristic pattern on an electrocardiogram: narrow QRS complexes and periods where the atria and ventricles beat independently of each other.¹ Though relatively uncommon compared to other fast heart rhythms, junctional tachycardia matters because it can be difficult to distinguish from similar-looking arrhythmias, and when it persists, it can weaken the heart.

How Junctional Tachycardia Differs From Other Fast Rhythms

The heart’s electrical system normally fires from the sinus node at the top of the right atrium, travels through the AV node, and then spreads to the ventricles. In junctional tachycardia, the AV node or nearby tissue starts generating its own rapid impulses, essentially overriding the sinus node’s normal pacemaker role. The underlying mechanism is most likely abnormal automaticity or triggered activity rather than the re-entry circuits that drive many other supraventricular tachycardias.²

This distinction matters for treatment. Re-entrant arrhythmias, like the common AV nodal re-entrant tachycardia (AVNRT), involve an electrical signal looping in a circle through two pathways. Those circuits can often be interrupted with specific maneuvers or precisely targeted ablation. Junctional tachycardia, by contrast, behaves more like a rogue pacemaker cell firing too quickly on its own. It does not respond to the same tricks that break a re-entry loop, which is one reason it can be stubborn to treat.

The confusion between junctional tachycardia and AVNRT is not just academic. On a standard ECG, the two can look remarkably alike, especially when the junctional rhythm conducts backward to the atria in a one-to-one fashion through the fast pathway. Specialized pacing maneuvers during an electrophysiology study are often needed to tell them apart.³ Even then, clinicians must consider the possibility of other unusual narrow-complex re-entrant rhythms that can mimic both conditions.⁴

The Two Main Settings Where It Appears

Junctional tachycardia shows up in two very different clinical situations, and the distinction is important because the outlook and treatment differ considerably.

After Heart Surgery

The most common scenario, especially in children, is junctional ectopic tachycardia (JET) appearing in the hours or days after open-heart surgery for congenital heart defects. The physical trauma of surgery near the AV node, the inflammation that follows, and the effects of cardiopulmonary bypass all contribute. Longer bypass times and higher levels of a cardiac injury marker called troponin are significant risk factors, and elevated body temperature at the onset of the arrhythmia nearly reaches statistical significance as a predictor as well.⁵ This postoperative form is usually temporary, resolving within days as inflammation settles, though it can cause serious hemodynamic problems while it lasts because the fast, uncoordinated rhythm undermines the heart’s pumping efficiency at a moment when the heart is already recovering from surgery.

Without Prior Surgery

The congenital form of JET appears in infants and young children who have not undergone any cardiac procedure. This version is far rarer and far more dangerous. It tends to be incessant, meaning the tachycardia is present most of the time rather than coming and going. Heart rates in one multicenter study of 26 patients ranged from 140 to 370 beats per minute, with a mean around 230, and AV dissociation was a defining feature on the ECG.⁶ Over half of those patients developed heart failure, and the overall mortality was about 35%.⁷ Among survivors, some were eventually able to stop treatment without complications, sometimes as young as ten months old, suggesting that the arrhythmia substrate can mature or resolve over time in certain cases.⁶

Adults can develop focal junctional tachycardia as well, though it is uncommon enough that early reports described it mainly in small case series. Five adults characterized in one study had rapid, irregular paroxysmal episodes with rates between 120 and 250 beats per minute, distinct from the slower, more benign “nonparoxysmal” junctional rhythms that cardiologists sometimes see in other contexts.¹

Symptoms and When the Heart Starts to Suffer

Symptoms largely depend on how fast the heart is going, how long the tachycardia lasts, and whether the person’s heart is otherwise healthy. Brief or slow episodes might produce nothing more than a feeling of palpitations or mild lightheadedness. Sustained episodes at higher rates can cause chest discomfort, shortness of breath, fatigue, and dizziness. In infants, who cannot report symptoms, irritability, poor feeding, and rapid breathing are the clues.

The real danger comes when junctional tachycardia is incessant or present for large portions of the day. In a long-term follow-up of patients with a related variant called permanent junctional reciprocating tachycardia, Holter monitoring showed the arrhythmia was present for more than half of a 24-hour period in roughly 70% of patients. About 28% developed tachycardia-related cardiomyopathy, meaning their heart muscle weakened specifically because it had been beating too fast for too long. Heart failure symptoms in those patients ranged from mild to severe.⁸ The good news is that tachycardia-related cardiomyopathy is often reversible once the arrhythmia is controlled.

Patients with focal junctional tachycardia tend to be “quite symptomatic,” as one review put it, and if the tachycardia is incessant and left untreated, heart failure can develop.² This is why even people whose symptoms feel tolerable should not ignore a confirmed junctional tachycardia diagnosis. The heart can silently deteriorate if the rhythm goes unchecked for weeks or months.

Other Triggers and Causes

Beyond the surgical and congenital settings, junctional tachycardia can pop up in the context of acute heart inflammation. Myocarditis, an inflammation of the heart muscle usually triggered by a viral infection or autoimmune reaction, has been reported to produce accelerated junctional rhythms. In one case, a patient with Graves’ disease presented with myocarditis manifesting as an accelerated junctional rhythm alongside the more typical findings of arrhythmia, shortness of breath, and elevated cardiac enzymes.⁹ This is a rare presentation, but it underscores that the AV junction is sensitive to inflammatory and metabolic insults.

Digitalis toxicity is another classic trigger. Digoxin, a medication used for heart failure and certain arrhythmias, can paradoxically cause junctional tachycardia when its levels in the blood get too high. The drug enhances automaticity in the AV junction while simultaneously slowing conduction elsewhere, creating the perfect conditions for a junctional rhythm to take over. Other potential triggers include acute ischemia (reduced blood flow to the heart), electrolyte imbalances, and stimulant drugs, though these are less commonly documented as causes of true junctional tachycardia specifically.

Drug Treatment

The approach to medication depends heavily on whether you are dealing with a postoperative child or an adult with idiopathic disease, but some themes are consistent. The arrhythmia is often stubborn, and no single drug works reliably in all patients.

For postoperative JET in children, the strategy combines cooling the body (mild hypothermia to reduce metabolic demand and slow the junctional rate), minimizing stimulants like catecholamines when possible, correcting electrolytes, and using antiarrhythmic drugs. Amiodarone is the most widely used first-line medication. In one study of 40 postoperative patients treated with amiodarone, the drug was effective in about 45% of cases: sinus rhythm was restored in seven patients, and the heart rate dropped significantly in eleven more, from a median of 180 down to 142 beats per minute, enough to allow effective atrial pacing to restore AV synchrony.¹⁰ Patients with larger differences between arterial and venous oxygen saturation and lower body temperatures were less likely to respond, suggesting that the sickest patients with the worst hemodynamics had more refractory disease.

Procainamide is another option, and intravenous flecainide has shown impressive results in small series. In a study of seven postoperative patients given IV flecainide, sinus rhythm was restored in all of them after a mean of about seven hours. Heart rate fell from around 219 to 136 beats per minute, blood pressure rose, and central venous pressure dropped, all signs of improved cardiac output. No side effects or recurrences were noted.¹¹ The sample was small, but the results were striking enough to keep flecainide in the toolkit. Ivabradine, a drug that slows heart rate by a different mechanism than traditional antiarrhythmics, has also shown promise and is increasingly being studied for this indication.⁴

In adults with focal junctional tachycardia, beta-blockers are a reasonable starting point. Early case series found that all patients responded at least somewhat to beta-blockers, though for some a combination of procainamide and propranolol proved more effective than either alone.¹ The general pattern with idiopathic JET in adults, however, is that it tends to be refractory to antiarrhythmic agents, which pushes patients and clinicians toward catheter ablation.

Catheter Ablation and Its Risks

Ablation for junctional tachycardia is a very different proposition from ablation for something like AVNRT, where success rates routinely exceed 95% with minimal risk. Because junctional tachycardia originates in or immediately adjacent to the AV node, ablating the arrhythmia focus means working in dangerously close proximity to the conduction system that keeps the heart beating in a coordinated fashion. Damage the AV node, and the patient may need a permanent pacemaker.

In a multicenter study of 15 adults with idiopathic JET who underwent catheter ablation (almost all with radiofrequency energy), the acute success rate was 100%, meaning the tachycardia stopped during the procedure in every case. But the recurrence rate was 53%, with more than half of patients needing at least one repeat procedure. Worse, 20% developed high-grade AV block requiring a permanent pacemaker.¹² Those numbers illustrate the fundamental tension with this arrhythmia: the procedure works in the short term but carries a real risk of trading one problem (tachycardia) for another (pacemaker dependence).

Cryoablation, which uses freezing instead of heat, offers a potential safety advantage. Because cryoenergy creates a reversible lesion before it becomes permanent, the operator can test whether a given spot will cause AV block before committing to a full ablation. A study evaluating cryoablation in patients at high risk of AV block reported a primary success rate of 92% with no permanent AV block. The trade-off was a recurrence rate of 29%, compared to about 9% for radiofrequency ablation in the same study.¹³ So cryoablation is safer for conduction but less durable, often requiring more procedures to achieve lasting control.

For patients who have failed drug therapy and face high ablation risk, a last-resort option remains full AV junction ablation followed by permanent pacemaker implantation. This eliminates the tachycardia entirely by destroying the AV node on purpose and replacing its function with a device. The risk of AV block from selective ablation of just the tachycardia focus (as opposed to the entire node) is estimated at roughly 5 to 10%.²

Prognosis After Postoperative JET

For children who develop JET after congenital heart surgery, the news is cautiously reassuring. The arrhythmia itself adds hemodynamic stress at a vulnerable moment, but in one study comparing outcomes between children who developed JET and those who did not, mortality was 8% in the JET group versus 5% in controls, a difference that was not statistically significant. When the researchers accounted for other factors in a regression model, JET was not an independent risk factor for death.⁵ The implication is that while postoperative JET is a marker of a more complicated surgical course, it does not independently doom the patient. With aggressive rate control, cooling, and pharmacotherapy, most children survive the episode and go on to recover.

The congenital form carries a grimmer outlook when uncontrolled, with the roughly 35% mortality rate mentioned earlier. But among survivors, spontaneous improvement or resolution can occur as the child grows, and some patients are able to discontinue therapy entirely. Whether the arrhythmia truly resolves or simply becomes subclinical enough to stop causing problems is not always clear, but the practical outcome for families is encouraging.

Why Diagnosis Is Harder Than It Sounds

If you have read this far, you might assume a competent cardiologist could glance at an ECG and immediately identify junctional tachycardia. In reality, the diagnosis is one of the trickier calls in cardiac electrophysiology. The ECG shows a narrow-complex tachycardia, which is a feature shared by a long list of arrhythmias including AVNRT, atrial tachycardia, orthodromic accessory pathway tachycardia, and others. The presence of AV dissociation, when the atria and ventricles beat at different rates, is a useful clue favoring junctional tachycardia over re-entrant mechanisms, but it is not always obvious on a standard 12-lead ECG.

An electrophysiology study, where catheters are threaded into the heart to record electrical activity directly, is often the definitive diagnostic tool. Specific pacing maneuvers can distinguish junctional tachycardia from AVNRT. The logic works like this: if a carefully timed premature stimulus delivered to the atrium can advance the next ventricular beat without stopping the tachycardia, that argues against AVNRT (where the re-entry circuit depends on backward conduction through a specific pathway) and favors junctional tachycardia.³ But even experienced electrophysiologists acknowledge the challenge. After ruling out AVNRT, one must also consider the possibility of unusual narrow-complex re-entrant circuits originating below the atrium that can mimic both AVNRT and junctional tachycardia on standard pacing maneuvers.⁴

Getting the diagnosis right is not just an intellectual exercise. Misdiagnosing junctional tachycardia as AVNRT could lead to an ablation strategy targeting the wrong substrate, with the potential for both failure and unnecessary AV node damage. Conversely, misdiagnosing AVNRT as junctional tachycardia might lead a clinician to avoid ablation out of excessive caution when it could actually be performed safely and curatively.

Living With Junctional Tachycardia as an Adult

For the adult with idiopathic focal junctional tachycardia, the path forward usually involves a period of drug trials followed by a decision about ablation. Beta-blockers or antiarrhythmics may control the rate enough to prevent symptoms and protect heart function, and some people do well on medications for years. But for those who remain symptomatic or who develop signs of cardiomyopathy despite drug therapy, ablation becomes the more appealing option even with its risks.

The conversation with an electrophysiologist will typically center on how symptomatic the tachycardia is, whether there is any evidence of declining heart function on echocardiography, and how close the arrhythmia focus appears to the compact AV node on imaging. For foci that sit a comfortable distance from critical conduction tissue, radiofrequency ablation can be attempted with reasonable confidence. For riskier locations, cryoablation offers a safer first attempt with the understanding that recurrence may require repeat procedures. The one-in-five chance of needing a permanent pacemaker reported in the multicenter adult ablation study is a number worth discussing frankly, since it applies to the cumulative risk across initial and repeat procedures.¹²

Some adults live with a controlled junctional tachycardia for years without major problems, particularly if the rate stays moderate and the rhythm is not present continuously. Regular follow-up with echocardiograms to monitor heart function is essential, since tachycardia-related cardiomyopathy can develop insidiously. The heart may look fine for a long time and then show signs of dilation or weakened squeezing only after months of sustained rapid rates. Catching that trend early is the best way to prevent irreversible damage.

1
PubMed. Clinical and electrophysiologic characterization of automatic junctional tachycardia in adults
2
PubMed. Role of invasive electrophysiologic testing in the evaluation and management of adult patients with focal junctional tachycardia
3
PubMed. Differentiating junctional tachycardia and atrioventricular node re-entry tachycardia based on response to atrial extrastimulus pacing
4
PubMed Central. Diagnosis and management of junctional ectopic tachycardia in children
5
European Journal of Cardio-Thoracic Surgery. Junctional ectopic tachycardia after surgery for congenital heart disease: incidence, risk factors and outcome
6
PubMed. Evolving concepts in the management of congenital junctional ectopic tachycardia. A multicenter study
7
PubMed Central. Junctional ectopic tachycardia in infants and children
8
PubMed. Permanent junctional re-entry tachycardia. A multicentre long-term follow-up study in infants, children and young adults
9
PubMed Central. Acute myocarditis presenting as accelerated junctional rhythm in Graves’ disease: A case report
10
PubMed. Amiodarone as a first-line therapy for postoperative junctional ectopic tachycardia
11
PubMed. Intravenous flecainide for the treatment of junctional ectopic tachycardia after surgery for congenital heart disease
12
PubMed. Outcomes of junctional ectopic tachycardia ablation in adult population-a multicenter experience
13
Archives of Cardiovascular Diseases. Cryoablation of junctional tachycardia at high risk of atrio-ventricular block